{"meshTags":["Antineoplastic Combined Chemotherapy Protocols","Drug Screening Assays, Antitumor","Drug Delivery Systems","Drug Administration Schedule","Treatment Outcome","Humans","Drug Design","Administration, Oral","Time Factors","Randomized Controlled Trials as Topic","Erlotinib Hydrochloride","Taxoids","Carcinoma, Non-Small-Cell Lung","Receptor, Epidermal Growth Factor","Expert Testimony","Quinazolines","Clinical Trials, Phase III as Topic","Antineoplastic Agents"],"meshMinor":["Antineoplastic Combined Chemotherapy Protocols","Drug Screening Assays, Antitumor","Drug Delivery Systems","Drug Administration Schedule","Treatment Outcome","Humans","Drug Design","Administration, Oral","Time Factors","Randomized Controlled Trials as Topic","Erlotinib Hydrochloride","Taxoids","Carcinoma, Non-Small-Cell Lung","Receptor, Epidermal Growth Factor","Expert Testimony","Quinazolines","Clinical Trials, Phase III as Topic","Antineoplastic Agents"],"publicationTypes":["News"],"title":"Erlotinib hydrochloride.","pubmedId":"15690599"}